Remove Antibody Remove Gene Expression Remove In-Vitro Remove Protein
article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3. This is a common reaction within peptide chemistry and it has been approved by regulatory authorities for various antibody-drug conjugates 4. Nanoparticles 6.

article thumbnail

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein.

RNA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from SLAS Europe 2023

Drug Discovery World

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology.

Doctors 52
article thumbnail

Bristol Myers Squibb Statement on Istodax® (romidepsin) Relapsed/Refractory Peripheral T-cell Lymphoma U.S. Indication

The Pharma Data

In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the U.S. Based on this outcome, Bristol Myers Squibb made the decision to withdraw the PTCL indication from the U.S. senior vice president, Hematology Development, Bristol Myers Squibb.

Nurses 52